{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-323787","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2025-12-18T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.453036+00:00","generated_at":"2026-05-16T12:46:07.177686+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Werewolf Therapeutics reports 21% ORR for WTX-124 in melanoma, seeks partnerships for INDUKINE programs","bullets":["WTX-124 monotherapy achieved 21% ORR in heavily pretreated advanced melanoma; 30% ORR in patients not primary resistant to prior immunotherapy.","FDA accepted 18 mg as recommended dose for WTX-124; provided guidance for registration path in post-ICI advanced melanoma.","WTX-330 showed one confirmed partial response in metastatic gall bladder cancer with 45% tumor reduction; favorable tolerability.","Company shifting focus to INDUCER T-cell engager platform; IND filings for WTX-1011 (STEAP1) and WTX-2022 (CDH6) planned mid-2027 pending funding.","Additional funding required to initiate further development of both INDUKINE and INDUCER programs; seeking strategic partners."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-323787","json":"https://secwatch.observer/filing/0001193125-25-323787.json","markdown":"https://secwatch.observer/filing/0001193125-25-323787.md","text":"https://secwatch.observer/filing/0001193125-25-323787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/0001193125-25-323787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312525323787/d21464d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T12:46:07.177686+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}